An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Use of routine thoracentesis in addition to medical therapy yielded no significant benefits for adults with heart failure and pleural effusions, according to a new study.

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.